What are the initiation criteria, dosing schedule, and monitoring requirements for Qelbree (viloxazine) in patients aged 6 years or older with ADHD?

Qelbree (Viloxazine Extended-Release) for ADHD: Initiation, Dosing, and Monitoring

Qelbree is initiated without specific prerequisite criteria beyond confirmed ADHD diagnosis in patients ≥6 years, with age-based starting doses of 100 mg daily (ages 6-11), 200 mg daily (ages 12-17 and adults), followed by weekly titration and mandatory cardiovascular monitoring before treatment, after dose increases, and periodically throughout therapy. 1

Patient Selection and Contraindications

Absolute Contraindications

• Concomitant MAOI use or within 14 days of MAOI discontinuation 1
• Concurrent use of sensitive CYP1A2 substrates or those with narrow therapeutic range 1

Pre-Treatment Screening Requirements

Before initiating Qelbree, assess the following:

• Cardiovascular parameters: Baseline heart rate and blood pressure 1
• Psychiatric history: Screen for bipolar disorder risk, including personal/family history of suicide, bipolar disorder, and depression 1
• Suicidality risk: Establish baseline using Columbia-Suicide Severity Rating Scale (C-SSRS) 1
• Renal function: Identify severe renal impairment requiring dose adjustment 1

Age-Specific Dosing Schedules

Pediatric Patients Ages 6-11 Years

• Starting dose: 100 mg once daily 1
• Titration: Increase in 100 mg weekly increments as needed 1
• Maximum dose: 400 mg once daily 1
• Optimal therapeutic range: 200-400 mg daily (moderate doses provide best outcomes) 2

Adolescent Patients Ages 12-17 Years

• Starting dose: 200 mg once daily 1
• Titration: May increase by 200 mg after 1 week 1
• Maximum dose: 400 mg once daily 1

Adult Patients

• Starting dose: 200 mg once daily 1
• Titration: Increase in 200 mg weekly increments 1
• Maximum dose: 600 mg once daily 1

Special Population: Severe Renal Impairment

• Starting dose: 100 mg once daily (all ages) 1
• Titration: Increase in 50-100 mg weekly increments 1
• Maximum dose: 200 mg once daily 1

Administration Instructions

Qelbree capsules may be swallowed whole OR opened with entire contents sprinkled onto applesauce or pudding for immediate consumption. 1 This flexibility is particularly valuable for younger children who cannot swallow capsules.

Timing flexibility: Qelbree can be administered in the morning or evening without affecting efficacy, safety, or sleep outcomes. 3 This allows dosing to be adjusted based on individual tolerability patterns.

Mandatory Monitoring Requirements

Cardiovascular Monitoring

Assess heart rate and blood pressure at three critical timepoints:

• Before initiating treatment 1
• Following each dose increase 1
• Periodically during maintenance therapy (recommended quarterly based on stimulant monitoring standards) 4, 1

Cardiovascular Effects to Monitor

In pediatric patients (6-17 years):

• 29% experienced ≥20 bpm heart rate increase at some point during treatment 1
• 13% had ≥15 mmHg diastolic blood pressure increase 1

In adults:

• 29% experienced ≥20 bpm heart rate increase 1
• 13% had ≥15 mmHg diastolic blood pressure increase 1

Psychiatric Monitoring

Monitor closely for suicidal thoughts and behaviors, particularly during initial weeks of treatment. 1 Higher rates of suicidal ideation were reported in Qelbree-treated patients versus placebo in clinical trials, warranting the FDA boxed warning. 1

Screen for activation of mania or hypomania, especially in patients with risk factors for bipolar disorder. 1

Safety Monitoring for Common Adverse Effects

Monitor for the following adverse reactions (≥5% incidence and twice placebo rate):

Pediatric patients (6-17 years):

• Somnolence (16% vs 4% placebo) 1
• Decreased appetite (7% vs 0.4% placebo) 1
• Fatigue (6% vs 2% placebo) 1
• Nausea, vomiting, insomnia, irritability 1

Adult patients:

• Insomnia, headache, somnolence (6% vs 2% placebo) 1
• Fatigue (12% vs 3% placebo) 1
• Nausea, decreased appetite, dry mouth, constipation 1

Weight Monitoring

Track weight changes, particularly in younger children:

• Children 6-11 years gained average 0.2 kg (vs 1 kg with placebo) 1
• Adolescents 12-17 years lost average 0.2 kg (vs 1 kg gain with placebo) 1

Expected Timeline for Therapeutic Response

Symptom improvement typically begins within 2-3 weeks of treatment initiation. 5 This is faster than atomoxetine (6-12 weeks) but slower than stimulants (days). 4

The dose-response curve is bell-shaped, with optimal efficacy at moderate doses (200-400 mg or 6-8 mg/kg). 2 Doses exceeding 400 mg or 7 mg/kg may not provide additional benefit. 2

Temporal trends show efficacy curves tapering at weeks 4-6, with continued improvement through 12 months and sustained effects beyond 24 months. 6, 5

Critical Clinical Pitfalls to Avoid

Do not exceed maximum recommended doses (400 mg for pediatric patients, 600 mg for adults), as higher doses are not associated with greater efficacy and may increase adverse effects. 1, 2

Do not overlook cardiovascular monitoring requirements. Nearly one-third of patients experience clinically significant heart rate increases, necessitating systematic vital sign assessment. 1

Warn patients about somnolence and fatigue risks before operating vehicles or machinery, as 16% of pediatric patients and 6% of adults experience somnolence. 1

Do not combine with MAOIs or sensitive CYP1A2 substrates, as these are absolute contraindications. 1

Discontinue Qelbree when pregnancy is recognized, as it may cause maternal harm. 1

Discontinuation Rates and Tolerability

Overall discontinuation due to adverse effects is low (3-8.2%), with most adverse events being mild to moderate in severity. 1, 6 The most common reasons for discontinuation are somnolence, nausea, headache, and irritability. 1

Long-term safety data through 72 months demonstrate sustained tolerability with no new safety concerns emerging during extended treatment. 6